MPT 0118
Alternative Names: MPT-0118Latest Information Update: 28 May 2024
Price :
$50 *
At a glance
- Originator Helmholtz Zentrum Munchen
- Developer Helmholtz Zentrum Munchen; Monopteros Therapeutics
- Class Antineoplastics; Phenothiazines; Small molecules
- Mechanism of Action MALT1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II B-cell lymphoma; Brain metastases; Ovarian cancer; Solid tumours
Most Recent Events
- 28 May 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (PO, Tablet)
- 20 Oct 2023 Safety, efficacy and pharmacokinetics data from a phase I/Ib trial in Solid tumours presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
- 06 Oct 2022 Phase-I/II clinical trials in B-cell lymphoma (Monotherapy) in USA (unspecified route) (Monopteros therapeutics pipeline oct 2022)